Y-mAbs stock soars after SERB Pharmaceuticals announces acquisition Investing.com -- Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) stock surged 103% following the announcement that SERB Pharmaceuticals will acquire the company in an all-cash transaction valued at approximately $412 million. Under the terms of the agreement, SERB will commence a tender offer to purchase all outstanding shares of Y-mAbs for $8.60 per share, representing a premium of approximately 105% to Y-mAbs’ closing price on August 4, 2025. The acquisition will add Y-mAbs’ lead commercial asset DANYELZA (naxitamab-gqgk), an FDA-approved treatment for relapsed or refractory high-risk neuroblastoma, to SERB’s portfolio of medicines for rare diseases. DANYELZA is the first FDA-approved treatment for this rare and aggressive pediatric cancer. The transaction was unanimously approved by Y-mAbs’ Board of Directors after a review of strategic alternatives to maximize stockholder value. The process included discussions with numerous potential buyers and consideration of additional capital sources to support pipeline development. "This transaction is a testament to our team’s hard work in building a strong foundation as a commercial organization with a differentiated, FDA-approved product in DANYELZA," said Michael Rossi, President and CEO of Y-mAbs. "By combining our expertise and resources with SERB’s specialty commercial capabilities, we can extend our shared commitment of improving the lives of even more patients and families on a global scale." SERB CEO Vanessa Wolfeler stated that the acquisition will allow the company to continue generating data for DANYELZA, expand partnerships to additional oncology centers, and have a positive impact on more neuroblastoma patients. Y-mAbs stockholders holding approximately 16% of outstanding shares have agreed to tender their shares. The transaction is expected to close by the fourth quarter of 2025. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. With YMAB making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed YMAB alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including YMAB, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is YMAB poised for similar growth? Don't miss the opportunity to find out.

Click Subscribe #YmAbs #SERBPharmaceuticals #StockMarket #Investing #PharmaNews

Y-mAbs Highlights Radiopharmaceutical Progress and Pipeline Expansion at R&D Update Phase 1 SADA Program Demonstrates Safety and Tumor Targeting; Company Unveils Broader Oncology Development Strategy Y-mAbs Therapeutics (Nasdaq: YMAB) shared

#YMAB highlights major strides in radiopharmaceuticals and pipeline growth at its latest R&D update. A promising leap in targeted cancer treatment.
#Biotech #Radiopharma #YMabs #CancerResearch
prismmarketview.com/y-mabs-highl...

Poster is up #SABCS24 - ongoing clinical trial DiG NKs enrolling at #mBC HER2- at The James @osuwexmed.bsky.social and supported by #Pelotonia and #SpielmanFund #yMAbs clinicaltrials.gov/study/NCT060...